Outsourced Pharma Capabilities Update June 2026: Cell Line Development

In this session, leading CDMO experts will break down the key decisions across host cell selection, vector design, and clone screening strategies, and explain how those choices impact expression, scalability, and long-term manufacturability.

These presentations will highlight how different CDMO approaches can reduce downstream risk or introduce it, as programs move from early development into tech transfer and commercial readiness.

If you are advancing a monoclonal antibody, recombinant protein, or next-generation biologic, this session will help clarify what to evaluate early—and what to avoid.